

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2015

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, -; B27, B51; Cw7, Cw12; DR1, DR11, DQ7, -

Summary of Results								
PBL/T-Cells					B-Cells			
Total tested	20	20	20	20	19	19	19	19
Positive	19	18	18	0	19	19	18	1
Negative	1	2	2	20	0	0	1	18
NT/Equivocal	1	1	1	1	1	1	1	1
% Positive	95.0%	90.0%	90.0%	0.0%	100.0%	100.0%	94.7%	5.3%
% Negative	5.0%	10.0%	10.0%	100.0%	0.0%	0.0%	5.3%	94.7%
Consensus	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
HLA Antibody (Defined By CDC)	B51	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17
Lab No.	Without DTT				Without DTT			
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
9	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
11	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
12	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
14	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Positive
15	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
20	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
23	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
24	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
25	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
28	Positive	Positive	Positive	Negative	Positive	Positive	Weak Positive	Negative
34	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
35	Positive	Positive	Positive	Negative				
38	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
39	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative
41	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative
42	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
45	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
51	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
54	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
58	NT	NT	NT	NT	NT	NT	NT	NT
62	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative

Concern with reliability of results due to viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A02/2015

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	8	6	6	0	4	4	4	0		90	90
11	6	6	6		6	6	6			90	90
12	45%	45%	45%	5%	40%	50%	40%	5%		90	90
14	8	6	6	0	8	8	8	2		90	80
15	8	4			8	4				90	90
20	9	9	9	1	9	9	9	1	80	90	90
23	8	8	8	1	8	8	8	1		90	90
24	100	90	90	10	80	80	80	20		90	80
25	8	8	8	1	8	8	8	1		99	99
28	6	6	8	1	4-6	6	4	1		99	95
34	8	8	6	1	8	8	8	1		99	99
35	6	6	4	1					60	70	
38	8	8	8	1	4	6	6	1	90	95	95
39	4		4		6	4	6		97		97
41					60%	100%	50%			95	95
42	80-100%	40%	60-80%		40-60%	60-80%	40-60%		95		90
45	8	8	8	1	6	8	6	1		99	90
51	8	8	8	0	8	8	8	0		95	95
54	90-100%	90-100%	60-70%	0-10%	80-90%	90-100%	60-70%	10-20%		99	90
58	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
62	8	8	8	0	8	8	6	0		100	90

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2015

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, -; B27, B51; Cw7, Cw12; DR1, DR11, DQ7, -

Summary of Results								
PBL/T-Cells					B-Cells			
Total tested	17	17	17	17	16	16	16	16
Positive	14	14	16	0	15	16	16	0
Negative	3	3	1	17	1	0	0	16
NT/Equivocal	1	1	1	1	1	1	1	1
% Positive	82.4%	82.4%	94.1%	0.0%	93.8%	100.0%	100.0%	0.0%
% Negative	17.6%	17.6%	5.9%	100.0%	6.3%	0.0%	0.0%	100.0%
Consensus	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
HLA Antibody (Defined By CDC)	B51	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17
Lab No.	With DTT				With DTT			
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
9	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
11	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
12	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
14	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
15	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
20	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
24	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
25	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
28	Negative	Negative	Positive	Negative	Positive	Positive	Positive	Negative
34	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
35	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
38	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
39	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative
41	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative
42	Positive	Weak Positive	Positive	Negative	Positive	Positive	Positive	Negative
45	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
51	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative
58	NT	NT	NT	NT	NT	NT	NT	NT

Concern with reliability of results due to viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A02/2015

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	8	6	6	0	4	4	4	0		90	90
11	8	8	6		8	8	6			90	90
12	45%	45%	45%	5%	40%	50%	40%	5%		90	90
14	8	6	6	0	8	8	8	0		90	80
15	8	6	4		6	4	6			90	90
20	9	9	9	1	9	9	9	1	80	90	90
24	100	100	90	10	90	80	80	20		90	80
25	8	8	8	1	6	8	8	1		99	99
28	1-2	1	8	1	6	4-6	6	1		99	95
34	8	8	8	1	8	8	8	1		99	99
35	4	4	2	1					60	70	
38	6	8	8	1	8	8	6	1	90	95	95
39			2			2	4		97		97
41					100%	100%	100%			95	95
42	60-80%	20-40%	40-60%		40-60%	60-80%	40-60%		95		90
45	8	8	8	1	6	6	6	1		99	90
51	8	8	8	0	6-8	6-8	6-8	0		95	95
58	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT